Davide Roccarina

Davide Roccarina

Auto-generated profile, based on publicly available information

Davide Roccarina

Department of Experimental and Clinical Medicine University of Florence Florence Italy

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
Aldo J. Montano-LozaAldo J. Montano-Loza
Aldo J. Montano-Loza
BHBettina Hansen
Bettina Hansen
CCChristophe Corpechot
Christophe Corpechot
DRDavide Roccarina
Davide Roccarina
DTDouglas Thorburn
Douglas Thorburn
AMAndrew Mason
Andrew Mason

28 June 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
CCChristophe Corpechot
Christophe Corpechot
FCFabrice Carrat
Fabrice Carrat
FGFarid Gaouar
Farid Gaouar
FCFrederic Chau
Frederic Chau
GHGideon Hirschfield
Gideon Hirschfield
VLVictor de Lédinghen
Victor de Lédinghen

6 August 2008 in Helicobacter
Verified
Journal Article
Open access
PDF file
HMHilde Moyaert
Hilde Moyaert
FFFrancesco Franceschi
Francesco Franceschi
DRDavide Roccarina
Davide Roccarina
RDRichard Ducatelle
Richard Ducatelle
FHFreddy Haesebrouck
Freddy Haesebrouck
Antonio GasbarriniAntonio Gasbarrini
Antonio Gasbarrini
The finding that Helicobacter pylori is the main cause of gastritis and peptic ulcer disease has opened a new era in the gastrointestinal world. Today there is evidence that H. pylori may also play a role in different nongastric diseases, opening the new “extragastric manifestations of H. pylori infection” field. Concerning this, several studies have been published in the last year. The most convincing data arise from those investigating idiopathic thrombocytopenic purpura and sideropenic anemia, while there is also an increasing evidence for a possible association with atherosclerotic disease. Furthermore, the discovery of a number of other novel Helicobacter species has stimulated the research in different extragastric diseases, in which an infectious hypothesis is plausible. In particular, several species have been studied for a potential role in different liver and intestinal diseases with interesting findings.

1 January 2015 in World Journal of Hepatology
Verified
Journal Article
Open access
DRDavide Roccarina
Davide Roccarina
In the last years, the development in the oncology field has been huge and rapid. In particular, the evaluation of response to anti-tumour treatments has been being object of intense research, producing significant changes. Response assessment after therapy in solid neoplasias has always used radiological imaging techniques, with tumour size reduction representing a presumed therapeutic efficacy. However, with the introduction of anti-angiogenetic drugs the evaluation of tumour size has become unsuitable because some tumours, under treatment, show only tumour perfusion changes rather than lesion shrinkage. Between different imaging techniques with contrast-enhancement, contrast-enhanced ultrasound (CEUS) and, in particular, dynamic CEUS have arisen as a promising and non-invasive device for monitoring cancer treatments. Moreover, the introduction of perfusion software has even more refined the technique since it is able to provide quantitative parameters related to blood flow and blood volume that can be associated with tumour response and clinical outcome such as the progression free survival and the overall survival. Here, we give an overview of the current status of CEUS in monitoring hepatocellular carcinoma response to different kind of treatments.

1 January 2013 in World Journal of Gastroenterology
Verified
Journal Article
Open access
DRDavide Roccarina
Davide Roccarina
MGMatteo Garcovich
Matteo Garcovich
MAMaria Elena Ainora
Maria Elena Ainora
GCGianluigi Caracciolo
Gianluigi Caracciolo
FPFrancesca Romana Ponziani
Francesca Romana Ponziani
MZMaria Assunta Zocco
Maria Assunta Zocco
Examinations with a visualisation of the anatomy and pathology of the gastrointestinal (GI) tract are often necessary for the diagnosis of GI diseases. Traditional radiology played a crucial role for many years. Endoscopy, despite some limitations, remains the main technique in the differential diagnosis and treatment of GI diseases. In the last decades, the introduction of, and advances in, non-invasive cross-sectional imaging modalities, including ultrasound (US), computed tomography (CT), positron-emission tomography (PET), and magnetic resonance imaging, as well as improvements in the resolution of imaging data, the acquisition of 3D images, and the introduction of contrast-enhancement, have modified the approach to the examination of the GI tract. Moreover, additional co-registration techniques, such as PET-CT and PET-MRI, allow multimodal data acquisition with better sensitivity and specificity in the study of tissue pathology. US has had a growing role in the development and application of the techniques for diagnosis and management of GI diseases because it is inexpensive, non-invasive, and more comfortable for the patient, and it has sufficient diagnostic accuracy to provide the clinician with image data of high temporal and spatial resolution. Moreover, Doppler and contrast-enhanced ultrasound (CEUS) add important information about blood flow. This article provides a general review of the current literature regarding imaging modalities used for the evaluation of bowel diseases, highlighting the role of US and recent developments in CEUS.

1 October 2024 in Radiology
Verified
Journal Article
Closed access
Giovanna FerraioliGiovanna Ferraioli
Giovanna Ferraioli
DRDavide Roccarina
Davide Roccarina
RBRichard G Barr
Richard G Barr
Substantial variability in US attenuation coefficient values across systems precludes their interchangeability for diagnosing and monitoring liver steatosis.